Observational studies and the difficult quest for causality: Lessons from vaccine effectiveness and impact studies by Lipsitch, Marc et al.
Observational studies and the difficult
quest for causality: Lessons from
vaccine effectiveness and impact studies
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Lipsitch, Marc, Ayan Jha, and Lone Simonsen. 2016. Observational
studies and the difficult quest for causality: Lessons from vaccine




Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions





ACCEPTED APRIL 2016 FOR PUBLICATION IN INTERNATIONAL JOURNAL OF 










1. Center	 for	 Communicable	 Disease	 Dynamics,	 Department	 of	 Epidemiology,	 Harvard	
T.H.	Chan	School	of	Public	Health,	677	Huntington	Avenue,	Boston,	MA	02115,	USA	



















































Although	vaccine	 licensure	 requires	evidence	of	 vaccine	 safety	and	efficacy	 from	 randomized	
controlled	trials	(RCT),	many	questions	about	vaccine	effectiveness	(VE)	can	be	answered	only	
by	observational	approaches	after	the	vaccine	is	in	use.	For	example,	the	effects	of	a	vaccine	on	
a	 rare	 outcome,	 such	 as	 mortality,	 can	 typically	 be	 studied	 only	 through	 observational	
approaches.	 Even	 within	 a	 RCT,	 the	 effects	 of	 a	 vaccine	 on	 a	 subgroup	 defined	 after	
randomization	 (and	 therefore	 not	 protected	 by	 randomization	 against	 confounding	 and	
selection	 bias)	 may	 be	 of	 interest;	 such	 subgroup	 analyses	 are	 observational,	 despite	 being	
nested	within	a	RCT.	 	Once	a	vaccine	is	 licensed	and	recommended	for	use,	certain	RCTs	may	
face	ethical	 challenges	 (1)	 ,	 though	 there	may	 remain	VE	questions	of	 interest.	 	 Finally,	RCTs	
randomized	 at	 the	 individual	 level	 are	 designed	 to	 measure	 only	 the	 direct	 protection	 the	
vaccine	 offers	 to	 vaccinated	 persons,	 but	 not	 the	 important	 overall	 effect	 of	 vaccination	 on	
disease	in	the	population,	including	that	achieved	by	indirect	protection	of	unvaccinated	people	
(herd	 immunity).	 Post-licensure	 observational	 studies	 --	 specifically	 ecological	 time-trend	
studies	comparing	population-level	disease	burdens	 in	the	pre-	and	post	vaccination	period	--	





case-control,	 and	 ecological	 studies.	 Such	 observational	 VE	 assessments	 are	 subject	 to	 the	
effects	of	confounding	and	other	forms	of	bias.	In	particular,	those	who	do	and	do	not	receive	a	
vaccine	may	differ	in	ways	that	affect	the	chance	of	experiencing	the	outcome	(e.g.	mortality	or	
infection).	 If	 so,	 these	 differences	 confound	 the	 measured	 effect	 of	 the	 vaccine	 on	 the	
outcome.	In	this	paper,	we	describe	approaches	to	identify,	address	and	reduce	the	impact	of	
such	confounding	in	observational	VE	studies.	We	provide	examples	of	each	approach	as	well	as	
a	 formal	 account,	 using	 causal	 directed	 acyclic	 graphs,	 of	 how	 each	 approach	 attempts	 to	
address	this	source	of	bias	and	what	assumptions	are	required	for	it	to	be	a	valid	approach.		
	




use	of	an	ecological	 time-trend	design	 to	measure	 indirect	and	overall	 causal	effects	 (5).	Our	
running	example	 is	 the	problem	of	estimating	 influenza	VE,	a	 recently	controversial	area	that	
illustrates	 how	 concerns	 about	 bias	 in	 the	 evidence	 base	 arose,	 how	 these	 approaches	 to	
reduce	or	detect	bias	are	used,	and	how	well	they	address	the	issues	we	are	raising.		Influenza	
VE	 studies	 raise	 nearly	 all	 the	 types	 and	 issues	 of	 potential	 bias,	 and	 all	 the	 strategies	 we	
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FIGURE	 2:	 As	 Figure	 1,	 but	 showing	 a	
negative	 control	 outcome	 D’	 (for	 example	
death	outside	of	influenza	season)	that	has	
no	 causal	 connection	 to	 vaccination	 but	








The	 use	 of	 negative	 controls	 to	 detect	 the	 existence	 and	 direction	 of	 bias	 has	 several	
advantages.	Under	the	assumptions	above,	negative	control	outcomes	can	detect	confounding	
and	other	forms	of	bias,	even	if	the	investigator	has	not	identified	the	likely	source	of	the	bias	
ahead	 of	 time.	 	 Similarly,	 if	 one	 has	 identified	 a	 potential	 confounder	 of	 the	 relationship	 of	
interest	 and	 wants	 to	 know	 whether	 it	 has	 been	 adequately	 controlled	 in	 an	 analysis,	 the	
analysis	can	be	applied	to	a	negative	control	outcome	to	find	out.		Indeed,	Jackson	et	al.	did	just	
that	to	test	the	adequacy	of	“standard”	statistical	approaches	(multiple	regression	modeling)	to	
controlling	 for	 health	 status	 in	 the	 elderly,	 and	 found	 that	 those	 had	 in	 fact	 been	
counterproductive	and	had	exacerbated	the	overestimate	of	VE	(6).		
	
The	principal	 limitation	of	 the	 negative	 control	 outcome	approach	 is	 that	 it	 does	 not	 offer	 a	
straightforward	 formula	 to	 correct	 for	 these	biases.	 It	 can	urge	 caution	but	 cannot	 solve	 the	
problem	 it	 identifies.	 However,	 identifying	 the	 bias	 may	 be	 a	 first	 step	 toward	 refining	 the	
analysis	to	reduce	it;	these	refined	analyses	may	then	be	submitted	to	negative	control	analyses	








attended	 infection,	 investigators	 often	 choose	 the	 case-control	 design	 for	 its	 ability	 to	 give	
results	 rapidly	and	with	moderate	sample	sizes.	As	 in	other	observational	designs,	vaccinated	
and	unvaccinated	persons	may	differ	 in	systematic	ways	that	may	 lead	to	confounding	of	the	
vaccine’s	 effect.	 An	 increasingly	 popular,	 convenient	 and	 cost-saving	 approach	 to	 such	 VE	
studies	 is	 the	 use	 of	 a	 "test-negative"	 control	 group.	 	 While	 “cases”	 in	 such	 studies	 are	
individuals	with	a	defined	clinical	syndrome	who	test	positive	 for	 the	pathogen	for	which	the	
vaccine	 is	 designed,	 “test-negative”	 controls	 are	 those	with	 the	 same	 clinical	 syndrome	who	
had	tested	negative	(1).	This	novel	approach	goes	by	different	names	and	is	sometimes	seen	as	
a	variant	of	the	case-control	approach	(26).	Because	it	differs	from	a	case-control	study	in	that	
participants	 are	 ascertained	 prior	 to	 knowledge	 of	 their	 outcome,	 without	 a	 fixed	 ratio	 of	
outcomes	in	the	study	(27),	it	could	be	seen	as	a	type	of	cohort	study;	indeed,	arguably	the	first	
test-negative	 vaccine	 study	 was	 called	 an	 “indirect	 cohort”	 study	 (28).	 To	 avoid	 semantic	
confusion	we	simply	call	it	the	test-negative	design.	The	motivating	idea	for	the	design	is	that,	if	
a	major	source	of	confounding	in	the	vaccination-disease	relationship	is	a	differential	tendency	



























































































































































Instead,	 they	 estimate	 the	 reduction	 in	 an	 outcome	 following	 vaccine	 introduction	 in	 a	
population,	 where	 the	 outcome	 is	 measured	 in	 individuals	 (who	 either	 die	 or	 survive)	 but	
summed	over	the	whole	population.	Thus,	such	studies	estimate	the	effect	of	a	change	in	the	
proportion	vaccinated	in	a	population	on	the	frequency	of	that	outcome	in	the	population	–	a	
causal	 quantity	 of	 policy	 relevance.	 Such	 studies	have	been	widely	used	 to	demonstrate	 and	




Time-trend	 VE	 studies	 aim	 to	measure	 a	 different	 quantity	 from	 the	 VE	 that	 is	 estimated	 in	
individual-level	 studies	 such	 as	 cohort	 and	 case-control	 studies.	 The	 impact	 of	 changing	
coverage	of	a	vaccine	 in	a	population	 is	of	considerable	 interest	to	policy	makers,	who	would	
like	 to	 know	 the	 number	 of	 cases	 that	 would	 be	 prevented	 under	 a	 vaccination	 program	
targeting	a	particular	 segment	of	 the	population.	Among	observational	designs,	 an	ecological	
study	 is	 uniquely	 appropriate	 to	measure	 exactly	 this	 quantity.	 For	 contagious	 diseases,	 the	
impact	 of	 vaccinating	 a	 substantial	 segment	 of	 the	 population	 will	 be	 a	 combination	 of	 the	
protection	 to	 vaccinees,	 and	 indirect	 (“herd	 immunity”)	 protection	 for	 those	 who	 are	 not	
immunized.	Here	the	terms	direct	and	indirect	are	used	in	their	infectious	disease	sense,	which	
differs	 from	 that	 typical	 in	 the	 causal	 inference	 literature	 (52).	 In	 infectious	 diseases	we	 use	




the	 assumption	 that	 vaccination	 and	 infection	 dynamics	 in	 one	 year	 do	 not	 affect	 those	 in	
future	 years.	 This	 is	 a	 simplification	 but	 a	 commonly-made	 one	 for	 influenza;	 relaxing	 this	
assumption	would	involve	complexity	beyond	our	scope.	We	show	the	hypothesized	routes	of	
vaccine	coverage	effect	on	infection:	direct	effects	on	the	vaccinees	(C>V>I)	and	indirect	effects	
through	 the	 vaccine	 status	 of	 other	members	 of	 the	 community	 on	 the	 infection	 risk	 of	 an	
individual	(C>V’>I)	Often	the	outcome	measured	is	mortality	or	hospitalization	(D).	
	
By	estimating	 the	causal	effect	of	 coverage	on	 the	 total	number	of	outcomes	of	 interest	 (for	










that	 are	 not	 eligible	 for	 vaccination,	 studying	 the	 indirect	 effect	 of	 the	 vaccine,	which	 is	 the	
impact	 of	 increased	 vaccine	 coverage	 in	 one	 age	 group	 on	 outcomes	 in	 another	 (3).	 This	
approach	 has	 also	 been	 used	 to	 study	 the	 indirect	 (herd	 immunity)	 benefits	 of	 infant	 PCV	
vaccine	use	as	a	way	to	protect	adults	(29,	49,	55,	56).		
	
For	 influenza,	 researchers	 in	 several	 countries	 used	 a	 time-trend	 study	 to	 estimate	 the	
reduction	 in	pneumonia	and	 influenza	mortality	 in	elderly	over	 a	 few	decades	as	 vaccination	
coverage	 in	 this	 age	 group	 increased	 from	 marginal	 to	 over	 65%	 --	 but	 failed	 to	 see	 any	
downward	 trends	 (15,	 57).	 It	was	 these	 studies	 that	 led	 to	 a	 re-examination	of	 the	evidence	
base	 from	 other	 observational	 studies	 that	 had	 reported	 astonishing	mortality	 benefits	 (14).			
Ultimately	 all	 of	 these	 efforts	 led	 to	 the	 understanding	 that	 more	 immunogenic	 vaccine	
formulations	may	be	needed	 for	 seniors,	 and	 the	 renewed	 interest	 in	pursuing	 strategies	 for	
influenza	control,	such	as	the	vaccination	of	“transmitters”	 including	children	to	achieve	herd	
protection	of	elderly	(58).	
FIGURE	4:	 In	 a	 time-trend	 study	 of	 vaccine	 effects,	
year	 (Y)	 affects	 vaccine	 coverage	 C,	 which	 can	 be	
interpreted	 as	 each	 individual’s	 risk	 of	 being	
vaccinated	V.	Coverage	also	affects	the	vaccination	
status	 of	 contacts	 V’,	 which	 affects	 (through	 herd	
immunity)	 an	 individual’s	 infection	 risk.	 The	
association	 between	 coverage	 and	 the	 outcome	 D	
(typically	 a	 severe	 one,	 such	 as	 pneumonia	 or	
death)	will	be	causal	if	year	is	affecting	the	outcome	
only	 through	 vaccine	 coverage	 and	 not	 through	




















vaccine	 effects.	 	 Like	 other	 observational	 studies,	 this	 design	 may	 suffer	 from	 confounding	
when	populations	that	have	different	levels	of	vaccine	coverage	also	differ	in	incidence	of	the	
outcome	 for	 reasons	 separate	 from	 the	 level	of	 vaccine	 coverage.	These	 confounding	 factors	
may	 include	 the	 age-distribution	 of	 the	 population,	 economy/development	 (which	 may	
influence	both	vaccine	coverage	and	risk	of	severe	outcomes	of	an	illness),	the	recent	incidence	
of	the	disease	in	the	population	(which	might	affect	the	prevalence	of	natural	immunity	to	the	




Y	 directly	 to	 D).	 In	 such	 a	 situation,	 it	 may	 be	 possible	 anticipate	 the	 direction	 of	 the	 bias	
induced	by	 such	 confounding,	 or	 even	 to	measure	 and	 adjust	 for	 it;	 for	 example,	 population	
aging	or	comparison	of	communities	with	different	age	structures	could	be	improved	by	using	




trend	 prior	 to	 vaccine	 introduction	 could	 be	 accounted	 for	 analytically,	 though	 there	 is	 no	













under	 study	 must	 be	 sufficiently	 specific	 so	 that	 the	 vaccine’s	 impact	 on	 it	 is	 likely	 to	 be	
measurable.	For	most	vaccines,	all-cause	mortality	is	so	nonspecific	that	the	true	causal	effect	
of	 an	 effective	 vaccine	would	be	expected	 to	be	only	marginal,	making	 a	 true	effect	 hard	 to	
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• Showed	 that	 the	 vaccine-preventable	 burden	 of	 influenza	mortality	 has	 been	 overestimated	
due	to	confounding	(6,	14,	15)		









similar	 for	 the	 test-negative	 design	 (74)	 and	 sometimes	 different	 (75);	 a	 comparison	 of	 per-
protocol	 results	 from	 RCTs	 versus	 estimates	 from	 test-negative	 observational	 studies	 of	 an	
influenza	vaccine	and	of	an	RSV	monoclonal	antibody	showed	close	concordance	(26)	.	
• Found	 that	 protection	 appears	 to	 decline	 over	 the	 course	 of	 influenza	 season,	 either	 due	 to	
waning	immunity	or	changing	composition	of	the	at-risk	group	(38-40)	
• Complemented	other	 study	designs	 to	produce	a	 consistent	 finding	 that	 the	2008-9	 seasonal	




• Confirmed	 traditional	 case-control	 findings	 of	 likely	 waning	 immunity	 after	 the	 5th	 dose	 of	
pertussis	vaccine	in	children,	with	similar	results	to	those	found	with	traditional	controls	(80)		
• Suggested	 that	 classical	 case-control	 design	 overestimates	 VE	 of	 reduced	 acellular	 pertussis	
(Tdap)	vaccines	in	adolescents	and	adults	(81)	










• Showed	 that	conjugate	vaccines	against	Hib	and	pneumococcal	disease	have	 large	direct	and	
indirect	effects	on	invasive	disease	hospitalizations	(2,	3,	84)		






Table 2.  Newer observational study designs and strategies used to measure VE and 
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